SCHEMBL6714043

SCHEMBL6714043

COc1cccc(OCC(=O)c2c3n(c4ccccc24)CCNCC3)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.55
HTR2C P28335 7/20 0.55
HTR6 P50406 2/20 0.45
GAA P10253 1/20 0.43
REN P00797 2/20 0.42
LMNA P02545 2/20 0.42
PKM P14618 1/20 0.40
ADRB1 P08588 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711392 0.91 HTR2A (0.58) HTR2AHTR2CHTR6GAAKDM4E
SCHEMBL6713586 0.89 HTR2A (0.63) HTR2AHTR2CGAARENKMT2A
SCHEMBL6715958 0.89 HTR2A (0.53) HTR2AHTR2CRENLMNAKDM4E
SCHEMBL6719307 0.88 HTR2A (0.55) HTR2AHTR2CHTR6RENLMNA
SCHEMBL6715470 0.88 HTR2A (0.55) HTR2AHTR2CGAARENKDM4E
SCHEMBL6715716 0.88 HTR2A (0.53) HTR2AHTR2CHTR6RENLMNA
SCHEMBL6711446 0.88 HTR2A (0.53) HTR2AHTR2CHTR6RENALDH1A1
SCHEMBL6713766 0.87 HTR2C (0.53) HTR2AHTR2CREN
SCHEMBL6719112 0.86 HTR2A (0.57) HTR2AHTR2CGAALMNAPKM
SCHEMBL6712398 0.86 HTR2C (0.58) HTR2AHTR2CHTR6GAAREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885HTR6 19/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885HTR6 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.